Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.275 +0.015 (+1.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Where Allogene Therapeutics Stands With Analysts
Via Benzinga
7 Short-Squeeze Stocks That Could Make You Rich
Although moving against the grain presents its own distinct set of risks, these short-squeeze stocks may profit the contrarian. 
Via InvestorPlace
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
7 Short-Squeeze Stocks That Could Explode in April
Although these short-squeeze stocks attracted bearish attention justifiably, contrarian sentiment may see them jump higher. 
Via InvestorPlace
Short Interest Update - Monday, March 27
Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today. 
Via Talk Markets
10 Analysts Have This to Say About Allogene Therapeutics
Via Benzinga
Allogene Therapeutics's Return On Capital Employed Insights
Via Benzinga
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
5 Analysts Have This to Say About Allogene Therapeutics
Via Benzinga
Expert Ratings for Allogene Therapeutics
Via Benzinga
Expert Ratings for Allogene Therapeutics
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings: 
Via Benzinga
Short Squeezes Have Returned in 2023 -- Here's Your Playbook
We haven't seen moves like these in a couple of years, so here's what investors should know. 
Via The Motley Fool
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
Allogene Therapeutics Inc (NASDAQ: ALLO) shares are trading higher by 13.1% to $7.76 Tuesday morning after the company announced data from its Phase 1 UNIVERSAL trial of ALLO-715 has been published in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
Via Benzinga
Amazon To Rally Over 28%? Here Are 10 Other Analyst Forecasts For Tuesday
Citigroup raised the price target for AT&T Inc. (NYSE: T) from $20 to $22. Citigroup analyst Michael Rollins maintained a Buy rating. AT&T shares fell 1% to $18.91 in pre-market trading. 
Via Benzinga
Yext, 1-800-Flowers.com And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
WWE, AMTD Digital And Some Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. AMTD Digital Inc. (NYSE: HKD) shares surged 118.8% to $65.54 in pre-market... 
Via Benzinga
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 63 companies set new 52-week lows. 
Via Benzinga
Top 10 Highest Short Interest Stocks And 10 With Highest Cost To Borrow: Where Do Carvana, MicroStrategy, Fisker And AMC Rank?
Investors often look for stocks with high short interest and a high cost to borrow, which could predict a potential short squeeze. New data shared by S3 Partners could signal which stocks investors are... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
-Clinical Data Due Next Week at ASH- 
Via Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.